Overview

Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that XOMA 052 is likely to improve glycemic control in subjects with Type 2 Diabetes Mellitus. The purpose of this study is to determine whether XOMA 052 improves glycemic control in subjects on Metformin monotherapy whose diabetes is still not adequately controlled.
Phase:
Phase 2
Details
Lead Sponsor:
XOMA (US) LLC